{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:59:55Z","timestamp":1783958395577,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>To assess the effects of IDegLira on glucometric indices deriving from intermittently scanned Continuous Glucose Monitoring (isCGM) in patients with type 2 diabetes (T2D).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Retrospective, observational, cohort, multi-center, \u201cpre \u2013 post\u201d study. All adults consecutively identified in the medical records who started treatment with IDegLira, and for whom an isCGM report before and after the initiation of IDegLira was available were included in the study. Time in range (TIR) represented the primary endpoint. Additional glucometric indices, insulin doses and body weight were also assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall, 87 patients were included by 5 diabetes centers [mean age 70.2\u2009\u00b1\u200911.0 years, mean duration of T2D 15.5\u2009\u00b1\u20099.6 years; BMI 29.4\u2009\u00b1\u20095.4\u00a0kg\/m<jats:sup>2<\/jats:sup>, baseline HbA1c 9.1\u2009\u00b1\u20092.1%, 33% insulin na\u00efve, 20.7% treated with basal-oral therapy (BOT), and 46% treated with multiple daily injections of insulin (MDI)]. After an average of 1.7 weeks from IDegLira initiation, TIR significantly increased from 56.8\u2009\u00b1\u200923.5% to 81.3\u2009\u00b1\u200913.5% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), TAR decreased from 42.3\u2009\u00b1\u200924.2% to 17.1\u2009\u00b1\u200913.6% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), while TBR remained steadily low (from 1.3\u2009\u00b1\u20092.3% to 1.4\u2009\u00b1\u20092.6%; <jats:italic>p<\/jats:italic>\u2009=\u20090.62). Estimated HbA1c decreased from 9.1\u2009\u00b1\u20092.1% to 6.7\u2009\u00b1\u20090.6% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and percentage of patients with a blood glucose coefficient of variation\u2009\u2265\u200936% dropped from 33.2 to 13.8% (<jats:italic>p<\/jats:italic>\u2009=\u20090.0005). In patients on MDI, the reduction in the total insulin dose was substantial (from 55.8\u2009\u00b1\u200931.2 IU to 27.2\u2009\u00b1\u200912.3 U).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In T2D patients with poor metabolic control, either insulin na\u00efve or treated with BOT or MDI, the introduction of IDegLira produces a significant increase in the time spent in good metabolic control and a marked reduction in glycemic fluctuations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00592-024-02361-7","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T05:02:29Z","timestamp":1725512549000},"page":"367-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9021-8238","authenticated-orcid":false,"given":"Maria Elena","family":"Malighetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-0243","authenticated-orcid":false,"given":"Laura","family":"Molteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1255-8437","authenticated-orcid":false,"given":"Emanuela","family":"Orsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3694-3620","authenticated-orcid":false,"given":"Roberta","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6414-9558","authenticated-orcid":false,"given":"Alessia","family":"Gaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9895-8916","authenticated-orcid":false,"given":"Federica","family":"Mazzoleni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3749-8801","authenticated-orcid":false,"given":"Filomena","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8900-1787","authenticated-orcid":false,"given":"Antonio Carlo","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"2361_CR1","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee (2024) 9. Pharmacologic approaches to Glycemic Treatment: standards of Care in Diabetes-2024. Diabetes Care 47:S158\u2013S178","journal-title":"Diabetes Care"},{"key":"2361_CR2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","volume":"29","author":"M Peyrot","year":"2012","unstructured":"Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM (2012) Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med 29:682\u2013689","journal-title":"Diabet Med"},{"key":"2361_CR3","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1089\/dia.2011.0022","volume":"13","author":"S Little","year":"2011","unstructured":"Little S, Shaw J, Home P (2011) Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther 13:S53\u201364","journal-title":"Diabetes Technol Ther"},{"key":"2361_CR4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1089\/dia.2010.0063","volume":"12","author":"D George","year":"2010","unstructured":"George D, Karim A, Florence M (2010) Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Diabetes Technol Ther 12:1019\u20131027","journal-title":"Diabetes Technol Ther"},{"key":"2361_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.pcd.2010.03.001","volume":"4","author":"J Dale","year":"2010","unstructured":"Dale J, Martin S, Gadsby R (2010) Insulin initiation in primary care for patients with type 2 diabetes: 3-year follow-up study. Prim Care Diabetes 4:85\u201389","journal-title":"Prim Care Diabetes"},{"key":"2361_CR6","first-page":"186","volume":"29","author":"LA Leiter","year":"2005","unstructured":"Leiter LA, Yale JF, Chiasson JL, Harris S, Kleinstiver P, Sauriol L (2005) Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 29:186\u2013192","journal-title":"Can J Diabetes"},{"key":"2361_CR7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.2337\/dc10-1710","volume":"34","author":"D Giugliano","year":"2011","unstructured":"Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K (2011) Efficacy of insulin analogs in achieving the hemoglobin A1c target of <\u20097% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care 34:510\u2013517","journal-title":"Diabetes Care"},{"key":"2361_CR8","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1111\/j.1464-5491.2012.03694.x","volume":"29","author":"BT Blak","year":"2012","unstructured":"Blak BT, Smith HT, Hards M, Maguire A, Gimeno V (2012) A retrospective database study of insulin initiation in patients with type 2 diabetes in UK primary care. Diabet Med 29:e191\u2013198","journal-title":"Diabet Med"},{"key":"2361_CR9","doi-asserted-by":"publisher","first-page":"110672","DOI":"10.1016\/j.diabres.2023.110672","volume":"199","author":"G Russo","year":"2023","unstructured":"Russo G, Di Bartolo P, Candido R, Lucisano G, Manicardi V, Giandalia A, Nicolucci A, Rocca A, Rossi MC, Di Cianni G, AMD Annals Study Group (2023) The AMD ANNALS: a continuous initiative for the improvement of type 2 diabetes care. Diabetes Res Clin Pract 199:110672","journal-title":"Diabetes Res Clin Pract"},{"key":"2361_CR10","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/ijcp.12384","volume":"68","author":"JPH Wilding","year":"2014","unstructured":"Wilding JPH (2014) The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract 68:682\u2013691","journal-title":"Int J Clin Pract"},{"key":"2361_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(18)30136-0","volume":"7","author":"A Ceriello","year":"2019","unstructured":"Ceriello A, Monnier L, Owens D (2019) Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol 7:221\u2013230","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2361_CR12","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/jcph.549","volume":"55","author":"C Kapitza","year":"2015","unstructured":"Kapitza C, Bode B, Ingwersen SH, Jacobsen LV, Poulsen P (2015) Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy. J Clin Pharmacol 55:1369\u20131377","journal-title":"J Clin Pharmacol"},{"key":"2361_CR13","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/jama.2016.1252","volume":"315","author":"I Lingvay","year":"2016","unstructured":"Lingvay I, Perez Manghi F, Garc\u0131a-Hernandez P et al (2016) Effect of insulin glargine up-titration vs insulin degludec\/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA 315:898\u2013907","journal-title":"JAMA"},{"key":"2361_CR14","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S2213-8587(19)30184-6","volume":"7","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Gonz\u00e1lez-Galvez G, Gr\u00f8n R, Halladin N, Haluz\u00edk M, Jermendy G, Kok A, \u0150rsy P, Sabbah M, Sesti G, Silver R (2019) Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol 7:596\u2013605","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2361_CR15","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2337\/dc17-1114","volume":"41","author":"LK Billings","year":"2018","unstructured":"Billings LK, Doshi A, Gouet D, Oviedo A, Rodbard HW, Tentolouris N, Gr\u00f8n R, Halladin N, Jodar E (2018) Efficacy and safety of IDegLira Versus basal-Bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care 41:1009\u20131016","journal-title":"Diabetes Care"},{"key":"2361_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","volume":"11","author":"T Battelino","year":"2023","unstructured":"Battelino T, Alexander CM, Amiel SA et al (2023) Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol 11:42\u201357","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2361_CR17","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2337\/dc17-1600","volume":"40","author":"T Danne","year":"2017","unstructured":"Danne T, Nimri R, Battelino T et al (2017) International consensus on use of continuous glucose monitoring. Diabetes Care 40:1631\u20131640","journal-title":"Diabetes Care"},{"key":"2361_CR18","doi-asserted-by":"publisher","first-page":"832","DOI":"10.2337\/dc16-1769","volume":"40","author":"L Monnier","year":"2017","unstructured":"Monnier L, Colette C, Wojtusciszyn A, Dejager S, Renard E, Molinari N, Owens DR (2017) Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care 40:832\u2013838","journal-title":"Diabetes Care"},{"key":"2361_CR19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1177\/19322968221149041","volume":"18","author":"A Philis-Tsimikas","year":"2024","unstructured":"Philis-Tsimikas A, Aroda VR, De Block C, Billings LK, Liebl A, Sivarathinasami R, D\u2019Cruz JM, Lingvay I (2024) Higher Derived Time in Range with IDegLira Versus insulin glargine U100 in people with type 2 diabetes. J Diabetes Sci Technol 18:653\u2013659","journal-title":"J Diabetes Sci Technol"},{"key":"2361_CR20","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s13300-023-01435-z","volume":"14","author":"E Martinka","year":"2023","unstructured":"Martinka E, Draveck\u00e1 I, Tk\u00e1\u010d I (2023) Switching from multiple insulin injections to a fixed combination of Degludec and Liraglutide in patients with type 2 diabetes Mellitus: results from the Simplify Study after 6 months. Diabetes Ther 14:1503\u20131515","journal-title":"Diabetes Ther"},{"key":"2361_CR21","doi-asserted-by":"publisher","unstructured":"Di Loreto C, Celleno R, Pezzuto D, Ambrosi F, Bellavita S, Biagini M, Passeri M, Del Sindaco P (2024) Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World Study. Diabetes Ther https:\/\/doi.org\/10.1007\/s13300-024-01564-z. Epub ahead of print. PMID: 38605275","DOI":"10.1007\/s13300-024-01564-z"},{"key":"2361_CR22","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/dom.15486","volume":"26","author":"GP Fadini","year":"2024","unstructured":"Fadini GP, Buzzetti R, Pitocco D, Tortato E, Scatena A, Lamacchia O, Lastoria G, Simoni L, Consoli A, REX study group (2024) IDegLira for the real-world treatment of type 2 diabetes in Italy. Final results from the REX observational study. Diabetes Obes Metab 26:1746\u20131756","journal-title":"Diabetes Obes Metab"},{"key":"2361_CR23","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1007\/s12325-022-02138-w","volume":"39","author":"Y Kawaguchi","year":"2022","unstructured":"Kawaguchi Y, Miyamoto S, Hajika Y, Ashida N, Hirota T, Masumoto K, Sawa J, Hamazaki K, Kumeda Y (2022) Efficacy of IDegLira Versus IDegAsp Therapy in patients with type 2 diabetes: a randomized crossover study by isCGM. Adv Ther 39:2688\u20132700","journal-title":"Adv Ther"},{"key":"2361_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13340-023-00681-7","volume":"15","author":"J Oya","year":"2024","unstructured":"Oya J, Nakagami T, Hasegawa Y, Kondo Y, Katamine A, Shimizu M, Kubota R, Suda R, Babazono T (2024) Effectiveness of insulin degludec\/liraglutide versus insulin degludec\/insulin aspart in Japanese patients with type 2 diabetes. Diabetol Int 15:237\u2013243","journal-title":"Diabetol Int"},{"key":"2361_CR25","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS (2019) Comparison of the effects of Glucagon-Like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for Prevention of Major adverse Cardiovascular and renal outcomes in type 2 diabetes Mellitus. Circulation 139:2022\u20132031","journal-title":"Circulation"},{"key":"2361_CR26","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.cmet.2024.05.001","volume":"36","author":"M Ben Nasr","year":"2024","unstructured":"Ben Nasr M, Usuelli V, Dellepiane S, Seelam AJ, Fiorentino TV, D\u2019Addio F, Fiorina E, Xu C, Xie Y, Balasubramanian HB, Castillo-Leon E, Loreggian L, Maestroni A, Assi E, Loretelli C, Abdelsalam A, El Essawy B, Uccella S, Pastore I, Lunati ME, Sabiu G, Petrazzuolo A, Ducci G, Sacco E, Centofanti L, Venturini M, Mazzucchelli S, Mattinzoli D, Ikehata M, Castellano G, Visner G, Kaifeng L, Lee KM, Wang Z, Corradi D, La Rosa S, Danese S, Yang J, Markmann JF, Zuccotti GV, Abdi R, Folli F, Fiorina P (2024) Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. Cell Metab 36:1302\u20131319e12","journal-title":"Cell Metab"},{"key":"2361_CR27","doi-asserted-by":"publisher","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","volume":"182","author":"G Bendotti","year":"2022","unstructured":"Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E, Assi E, Seelam AJ, El Essawy B, Jang J, Loretelli C, D\u2019Addio F, Berra C, Ben Nasr M, Zuccotti G, Fiorina P (2022) The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res 182:106320","journal-title":"Pharmacol Res"},{"key":"2361_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.clinthera.2016.11.001","volume":"39","author":"M Rondinelli","year":"2017","unstructured":"Rondinelli M, Rossi A, Gandolfi A, Saponaro F, Bucciarelli L, Adda G, Molinari C, Montefusco L, Specchia C, Chiara Rossi M, Scardapane M, Arosio M, Genovese S (2017) Use of Liraglutide in the Real World and Impact at 36 months on metabolic control, weight, lipid Profile, blood pressure, Heart Rate, and renal function. Clin Ther 39:159\u2013169","journal-title":"Clin Ther"},{"key":"2361_CR29","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2337\/dc13-2618","volume":"37","author":"A Ceriello","year":"2014","unstructured":"Ceriello A, Novials A, Canivell S, La Sala L, Pujadas G, Esposito K, Testa R, Bucciarelli L, Rondinelli M, Genovese S (2014) Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. Diabetes Care 37:1938\u20131943","journal-title":"Diabetes Care"},{"key":"2361_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pcd.2016.09.003","volume":"11","author":"K Khunti","year":"2017","unstructured":"Khunti K, Millar-Jones D (2017) Clinical inertia to insulin initiation and intensification in the UK: a focused literature review. Prim Care Diabetes 11:3\u201312","journal-title":"Prim Care Diabetes"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-024-02361-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-024-02361-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-024-02361-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T07:52:05Z","timestamp":1740815525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-024-02361-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["2361"],"URL":"https:\/\/doi.org\/10.1007\/s00592-024-02361-7","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The study protocol was approved by the Territorial Ethics Committee Lombardia 3, Italy (Prot. No. 278 \u2013 date January 3, 2024). Informed consent was obtained from all patients for being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Editorial assistance provided by CORESEARCH SRL (Maria Chiara Rossi, Giusi Graziano) and the Open Access fee was funded through a Novo Nordisk S.p.A. unconditional grant. The authors of the publication are fully responsible for the contents and conclusions. Novo Nordisk S.p.A. did not influence and has not been involved in the data interpretation presented in the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical writing and\/or editorial assistance"}}]}}